Vertex's sole drug on the market now, Kalydeco, treats only about 2,000 cystic fibrosis patients, at a cost of more than $300,000 a year per patient. Company executives priced the two-drug therapy, called Orkambi (pictured, at $259,000 per patient annually.read more >>